玻璃体内注射康柏西普治疗糖尿病黄斑水肿的观察

发布时间：2018-08-08 19:43

【摘要】：目的:观察玻璃体内注射康柏西普对糖尿病视网膜病变黄斑水肿的治疗效果。方法:经光相干断层扫描(OCT)检查证实的糖尿病视网膜病变所致的囊样黄斑水肿患者30例30眼,玻璃体内注射康柏西普0.05ml,术后1天观察视力,术后1周,3周,4周时,观察视力和OCT检查黄斑厚度改变。结果:治疗后1周,3周,4周时黄斑区视网膜厚度与治疗前相比,差异具有统计学意义,P0.001,术后1天,1周,3周,4周时视力较术前平均提升2行,术后4周部分患者出现轻度的囊样水肿。结论:玻璃体内注射康柏西普可有效治疗糖尿病视网膜病变所致的黄斑水肿,起效时间短,疗效确切,但应连续注射,连续注射的时间间隔不应超过4周。
[Abstract]:Objective: to observe the therapeutic effect of intravitreous injection of Compactopril on diabetic retinopathy macular edema. Methods: 30 eyes of 30 patients with cystic macular edema caused by diabetic retinopathy confirmed by optical coherence tomography (OCT) were injected intravitreous with Compacipe 0.05ml. the visual acuity was observed one day after operation, and the visual acuity was observed at 3 weeks and 4 weeks after operation. Visual acuity and macular thickness were observed by OCT. Results: there was a significant difference in macular retinal thickness between before and after treatment (P 0.001). The visual acuity of macular area increased by 2 rows at 1 week and 3 weeks and 4 weeks after treatment. Mild cystic edema was found in some patients 4 weeks after operation. Conclusion: intravitreous injection of Compactopril is effective in the treatment of macular edema caused by diabetic retinopathy. It is effective and effective, but it should be continuously injected and the interval of continuous injection should not be more than 4 weeks.
【作者单位】： 新疆维吾尔自治区人民医院眼科;
【分类号】：R587.2;R774.5
，

本文编号：2172857